Homepage
![]() |
Anna HakeMax-Planck-Institut für Informatik 66123 Saarbrücken, Germany |
|
email: | Anna.Hake@mpi-inf.mpg.de | |
phone: | +49 681 9325 3023 | |
fax: | +49 681 9325 3099 | |
room: | 523 (Building E1 4) |
Publications
-
Hake A, Pfeifer N
Prediction of HIV-1 sensitivity to broadly neutralizing antibodies shows a trend towards resistance over time
PLOS Computational Biology 2017 13(10): e1005789
-
Olga S. Voitenko; Andi Dhroso; Anna Feldmann; Dmitry Korkin; Olga V. Kalinina
Patterns of amino acid conservation in human and animal immunodeficiency viruses
Bioinformatics 2016 32 (17): i685-i692
-
J. F. Scheid*, Joshua A. Horwitz*, Y. Bar-On, E. F. Kreider, C.-L. Lu, J. C. C. Lorenzi, A. Feldmann, M. Braunschweig, L. Nogueira, T. Oliveira, I. Shimeliovich, R. Patel, L. Burke, Y. Z. Cohen, S. Hadrigan, A. Settler, M. Witmer-Pack, A. P. West, Jr., B. Juelg, T. Keler, T. Hawthorne, B. Zingman, R. M. Gulick, N. Pfeifer, G. H. Learn, M. S. Seaman, P. J. Bjorkman, F. Klein, S. J. Schlesinger, B. D. Walker, B. H. Hahn, M. C. Nussenzweig, and M. Caskey
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
Nature 2016, 535, pp 556–560
*: equal contribution -
T. Schoofs*, F. Klein*, M. Braunschweig*, K. F. Kreider, A. Feldmann , L. Nogueira, T. Oliveira, J. C. C. Lorenzi, E. H. Parrish, G. H. Learn, A. P. West, P. J. Bjorkman, S. J. Schlesinger, M. S. Seaman, J. Czartoski, M. J. McElrath, N. Pfeifer, B. H. Hahn, M. Caskey, and M. C. Nussenzweig
HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1
Science 2016, 352 (6288), pp 997-1001
*: equal contribution -
Feldmann A, Pfeifer N.
From predicting to analyzing HIV-1 resistance to broadly neutralizing antibodies
PeerJ PrePrints 3:e1304v1, 2015
Conference talks
- A. Feldmann and N. Pfeifer
From Predicting to Analyzing HIV-1 Resistance to Broadly Neutralizing Antibodies
German Conference on Bioinformatics , Dortmund, Germany 2015
Poster Presentations
-
A. Feldmann and N. Pfeifer
Further evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies - also in non-B subtypes
HIV Vaccines ,Olympic Valley, California USA, 2016.
-
A. Feldmann and N. Pfeifer
Estimating and Visualizing HIV-1 Susceptibility to Broadly Neutralizing Antibodies
Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 2015.
-
A. Feldmann and N. Pfeifer
Predicting and understanding HIV-1 susceptibility to broadly neutralizing antibodies
European Conference on Computational Biology, Strasbourg, France, 2014.